芬兰5个研究中心应用长效促性腺激素释放激 素增效剂(GnRH-a)(goserelin 3.6mg/28天)分别与低雌孕激素制剂NET(含17β-E_22mg及炔诺酮1mg)和安慰剂联合,对88例症状严重并经腹腔镜诊断为子宫内膜异位症进行了前瞻性随机双肓治疗研究,治疗期限为6个月。通过对两组患者治疗前后盆腔症状评分变化,腹腔镜AFS评分变化,血FSH、LH、E_2水平及药物所致低雌激素症状等进行比较,以评价GnRH-a与雌孕激素联合应用对子宫内膜异位症疗 In 5 research centers in Finland, GnRH-a (goserelin 3.6 mg / 28 days) and NET (including 17β-E 22 mg and norethindrone 1 mg) 88 patients with severe symptoms and laparoscopic diagnosis of endometriosis were prospective randomized double 肓 treatment study, the treatment period of 6 months. The changes of pelvic symptom scores, changes of laparoscopic AFS score, blood FSH, LH, E 2 levels and drug-induced low estrogen symptoms were compared between two groups before and after treatment to evaluate the effect of GnRH-a combined with estrogen and progesterone on the uterus Endometriosis treatment